Xiangsheng Medical is expected to increase its net profit in the first half of this year to increase by 50.48%year -on -year to 66.40%

On July 20, 2022, the Science and Technology Board Company Xiangsheng Medical (688358.SH) released the voluntary disclosure announcement of the 2022 semi -annual performance preview.

According to preliminary estimates of the financial department, it is expected that the net profit attributable to the owner of the parent company in 2022 is 71 million yuan to 78.51 million yuan. Compared with the same period of the previous year (legal disclosure data), it will increase by 23.8177 million yuan to 3,137,700 yuan Yuan, a year -on -year increase of 50.48%to 66.40%.

The company expects the net profit of non -recurring profit and loss to deduct the owner of the parent company in the first half of 2022 to the parent company owner of 69.6062 million yuan to 77.1162 million yuan. Compared with the same period of the previous year (legal disclosure data), it will increase from 24.5083 million yuan to 3,201.83. 10,000 yuan, a year -on -year increase of 54.34%to 71.00%.

According to the company's explanation, based on the company's continuous research and development investment and accumulation, the company's high -end color Doppler ultrasound products have obtained clinical and market attention and recognition continuously increased, and the proportion of sales has increased, which has driven the steady growth of the company's profit indicators.

In terms of the company's export business, the influence of overseas markets has gradually decreased, and market demand has gradually been released. The company actively deployed overseas localized marketing networks, continued to promote overseas channel construction, etc. to achieve the steady growth of the company's overseas business; Exchange income has increased, and it has also had a positive impact on the current net profit.

Faced with the domestic market with great growth potential, the company fully seized the opportunities such as domestic medical new infrastructure and encouraging domestic equipment procurement, introduced outstanding marketing management talents, and achieved simultaneous growth of domestic businesses.

During this report, it is expected that the amount of non -recurring profit and loss on the net profit attributable to shareholders of listed companies is about 1.3938 million yuan, which is reduced compared with the same period last year. It is mainly due to the reduction of government subsidies.

- END -